ACRI also holds a granted patent for this technology in the United States (US Patent # 8,956,878). ACRI's technology described in the patent includes the Vn96 peptide used for liquid biopsy applications. The peptide has a high affinity for heat shock proteins (HSPs) lining the surface extracellular vesicles (EVs). EVs contain a sample of the DNA, RNA, protein and metabolites found within the cells from which they are derived. Since EVs appear in blood, urine and other body fluids, they are a rich biomarker source that can be obtained by minimally-invasive methods to screen for diseases.
The ACRI team is working to identify the specific proteins and nucleic acids that are released from cancer cells in these small biomarker packets. These cancer-specific proteins and nucleic acids hold the potential to be used as new biomarkers for cancer detection using a liquid biopsy. ACRI is focused on advancing its extracellular vesicle capture technologies to enable new cancer diagnostic, prognostic, and treatment-response tests.
For technology information, collaborations or partnerships, please contact:
Remi Richard
Business Development Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +1 506 869 2048
Fax : +1 506 862 7571
